EVFM (Evofem Biosciences) Accounts Payable: $12.00 Mil (As of Mar. 2026)


What is Evofem Biosciences Accounts Payable?

Evofem Biosciences EVFM +0.42% Accounts Payable is $12.00 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

Evofem Biosciences's Accounts Payable for the quarter that ended in Mar. 2026 was $12.00 Mil.

Evofem Biosciences's quarterly Accounts Payable increased from Sep. 2025 ($11.62 Mil) to Dec. 2025 ($13.15 Mil) but then declined from Dec. 2025 ($13.15 Mil) to Mar. 2026 ($12.00 Mil).

Evofem Biosciences's annual Accounts Payable declined from Dec. 2023 ($17.02 Mil) to Dec. 2024 ($16.17 Mil) and declined from Dec. 2024 ($16.17 Mil) to Dec. 2025 ($13.15 Mil).

Evofem Biosciences Accounts Payable Related Terms

Evofem Biosciences Accounts Payable Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Accounts Payable Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.32 14.98 17.02 16.17 13.15

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.22 12.29 11.62 13.15 12.00

Evofem Biosciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $12.00 Mil mean?
Evofem Biosciences (EVFM) has a Accounts Payable of $12.00 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Evofem Biosciences and its competitors.
Is Evofem Biosciences' Accounts Payable too high?
Evofem Biosciences' current Accounts Payable is $12.00 Mil.
How does Evofem Biosciences' Accounts Payable compare to LYRA and CLSDQ?
Evofem Biosciences' Accounts Payable of $12.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current Accounts Payable is $12.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 5.1% below its estimated fair value. The current Accounts Payable is $12.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Accounts Payable is $12.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.